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Background: The 5-hydroxytryptamine type 3 antagonists, or setrons (eg, ondansetron), are 
commonly used for nausea and vomiting in the hospital setting. In 2001, droperidol was given 
a black box warning because it was found to prolong the QT interval and induce arrhythmias. 
The setrons share with droperidol the same potential proarrhythmic mechanisms, but limited 
data exist concerning their effects on the QT interval in individuals at high risk for torsades 
de pointes.
Methods: Forty hospitalized patients admitted for heart failure or acute coronary syndromes 
with one or more risk factors for torsades de pointes and an order for intravenous ondansetron 
4 mg were enrolled in this prospective, observational study. The QT interval corrected for heart 
rate (QTc) was obtained via a 12-lead electrocardiogram on admission and again 120 minutes 
after the first dose of ondansetron in order to determine the mean change in QTc following 
ondansetron exposure.
Results: The mean time interval between obtaining the baseline electrocardiogram and the 
  second electrocardiogram following ondansetron administration was 3.5 ± 2.14 hours. In the total 
population, the QTc interval was prolonged by 19.3 ± 18 msec (P , 0.0001) 120 minutes after 
ondansetron administration. For patients with an acute coronary syndrome and those with heart 
failure, QTc was prolonged by 18.3 ± 20 msec (P , 0.0001) and 20.6 ± 20 msec (P , 0.0012), 
respectively. Following ondansetron exposure, 31% and 46% in the heart failure and acute 
coronary syndromes groups, respectively, met gender-related thresholds for a prolonged QTc.
Conclusion: Our study found QTc prolongation due to ondansetron administration similar to 
that found in previous studies. When used in patients with cardiovascular disease (eg, heart failure 
or acute coronary syndromes) with one or more risk factors for torsades de pointes, ondansetron 
may significantly increase the QTc interval for up to 120 minutes after administration. From a 
patient safety perspective, patients who are at high risk for torsades de pointes and receiving 
ondansetron should be followed via telemetry when admitted to hospital.
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Introduction
Over the past two decades, the single most common cause of withdrawal or restriction 
of a medication that has already entered the market has been prolongation of the QT 
interval associated with polymorphic ventricular tachycardia or torsades de pointes.1 
Nine structurally unrelated drugs marketed in the United States for a wide range of 
noncardiovascular indications have since been removed or had their availability severely 
restricted due to this form of toxicity.1,2 In the hospital setting, numerous risk factors for Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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drug-induced QT interval prolongation potentially leading to 
torsades de pointes exist, including hypokalemia, hypomag-
nesemia, bradycardia, genetic predisposition, associated heart 
disease, female gender, and use of drugs that either prolong 
the QT interval or disrupt the metabolism or distribution of 
QT-prolonging drugs.3 In the class of QT-prolonging drugs, 
intravenous administration of medications can also be asso-
ciated with higher drug concentrations and greater cardiac 
exposure compared with oral dosing.3
In the postoperative setting, droperidol, as well as the 
5-hydroxytryptamine type 3 receptor antagonists, or setrons 
(eg, ondansetron), have been found to be very effective anti-
emetics for prevention or treatment of nausea and vomiting.4 
However, in 2001, the US Food and Drug Administration 
added a “black box” warning to the package labeling for 
droperidol regarding its potential proarrhythmic properties 
leading to QT prolongation.2 As a response to this warning, 
providers in the United States began to prescribe the setrons 
more widely due to patient safety issues. Furthermore, in 
2006, generic ondansetron entered the US market,   making 
the drug more widely available to providers and their 
patients. However, like droperidol, the setrons also possess 
the ability to block the myocardial KCNH2-encoded HERG 
(human ether-à-go-go related gene) potassium channel which, 
in theory, gives droperidol its proarrhythmic properties.5,6 
The HERG channel mediates the IKr (rapid component of 
the delayed rectifier potassium current) which is essential 
for phase 3 of repolarization of the cardiac action potential. 
Inhibition of this current results in prolongation of the dura-
tion of the action potential and a prolonged QT interval.5,6 
In addition, the setrons block sodium channels, resulting in 
lengthening of both depolarization and repolarization of the 
action potential.5
While case reports have been published documenting the 
proarrhythmic potential of setrons in both adults and children, 
overall electrocardiographic data have been conflicting.7–11 
Presently, only two prospective studies, conducted by the 
same investigators, have evaluated the effect of ondansetron, 
droperidol, and a combination of these agents on prolonga-
tion of the QT interval corrected for heart rate (QTc) at 
various time points following administration.12,13 In both 
studies, ondansetron was associated with a statistically sig-
nificant increase in mean maximal QTc lengthening of about 
17–20 msec (P , 0.0001). However, these findings were 
documented in patients who were either healthy volunteers 
or postoperative patients without additional risk factors for 
QTc prolongation. While these studies meet the criteria for 
assessing the effect of a drug on ventricular repolarization 
in humans established by the International Conference on 
Harmonization, their results do not always reflect a real 
world setting where the drug would be used in a patient with 
cardiovascular disease who may be at greater risk for QTc 
prolongation.14
Regarding patient safety, data generated in this patient 
population might assist health systems in their decisions to 
monitor the QTc interval more closely in those receiving 
setrons. The aim of this prospective observational study was 
to assess the effects of ondansetron on the mean QTc interval 
following the first dose in patients admitted to a coronary 
intensive care unit or step down unit with cardiovascular 
disease (eg, heart failure or acute coronary syndromes plus 
one additional risk factor for torsades de pointes).
Methods
Subjects
Study inclusion criteria consisted of admission with a princi-
pal diagnosis of either heart failure (ejection fraction , 40%) 
or acute coronary syndromes to the University of Colorado 
Hospital, being a patient in the coronary intensive care unit 
or step down unit between December 21, 2010 and July 1, 
2011, having a new medication order for 4 mg intravenous 
ondansetron, and one of the following risk factors for tor-
sades de pointes in the hospital setting: hypomagnesemia 
(,1.0 mEq/L) for .24 hours; hypokalemia (,3.2 mEq/L) 
for .24 hours; congenital long QT syndrome; baseline 
QTc .500 msec; female gender; heart failure (ejection 
fraction ,40%); acute coronary syndromes; old myocardial 
infarction; bradycardia (#50 beats per minute); or receiving 
more than one scheduled (not “as needed”) medication with 
an accepted or possible risk for torsades de pointes as per 
the Education and Research at the University of Arizona.1,3,15 
Patients were excluded if they were not placed on telemetry, 
had used ondansetron as a chronic medication or within the 
past four months, had already received a dose of ondansetron 
during their current hospitalization, or required a cardiac pace-
maker. This study was reviewed and granted exempt   status by 
the Colorado Multiple Investigation Review Board.
Study design
Patients were prospectively identified by a clinical pharmacist 
each morning by electronic pharmacy and medical admis-
sions records. As part of hospital procedure, each patient 
admitted to the coronary intensive care unit or step down 
unit with a primary cardiovascular diagnosis had a baseline 
12-lead electrocardiogram on admission conducted on the 
ward or in the emergency department. One hundred and Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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twenty minutes after the first dose of slow push intravenous 
ondansetron, the patient’s nurse obtained another 12-lead 
electrocardiogram. If the patient was also receiving a QTc-
prolonging medication, then the medication could not be 
given during this 120-minute time period. This 120-minute 
measurement interval was chosen because it was the middle 
of the dosing interval for ondansetron. The electrocardio-
graphic readings were analyzed and the QTc calculated 
by a cardiologist who was also blinded to the intent of the 
study. QTc prolongation was defined as .450 msec for men 
and .470 msec for women.3
The QT interval was measured by the following protocol. 
The anterior electrocardiogram lead in which the T wave 
had the largest amplitude was selected for QT interval mea-
surement in each subject.3 The QT interval was measured 
from the onset of the QRS complex to the end of the T wave, 
which was defined according to the criteria of Lepeschkin and 
  Surawicz.16 Because a notched T wave could represent T-U 
fusion, according to Lepeschkin and Surawicz, the intersec-
tion of the tangent to the downslope of the major repolariza-
tion wave with the isoelectric line was used in the presence 
of a T-U wave.16 The QT interval was corrected for heart rate 
according to the formula of Bazett (QTc = QT/√R × R).
Statistical analysis
Results are expressed as the mean ± standard deviation. To 
detect a QTc change from baseline greater than 10 msec with 
α and β risks of 0.05 and 0.20, respectively, and assuming a 
standard deviation of QTc change of 10 msec, a minimum of 
10 subjects was needed. However, 40 patients were analyzed 
so as to establish a normal distribution. Comparison of QTc 
before and after ondansetron exposure was analyzed using 
the Student’s paired t-test. All other variables were evaluated 
using descriptive statistics. All analyses were conducted using 
SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
Data were collected and analyzed for 40 patients (16 with a 
principal diagnosis of heart failure and 24 with a principal 
diagnosis of acute coronary syndromes). Table 1 summarizes 
the demographic and clinical characteristics of the patients 
studied. The mean age was 55 years in both the heart failure 
and acute coronary syndromes groups, with 50% of patients 
being women. In patients with heart failure, three patients 
had a baseline QTc that was already prolonged (range 
0.52–0.57 msec) as did five patients in the acute coronary 
syndromes group (range 0.50–0.57 msec). The majority of 
risk factors for QTc prolongation in both groups consisted 
Table 1 Demographic and clinical characteristics of patients
Characteristic Principal diagnosis on  
admission
Heart failure  
(n = 16)
ACS  
(n = 24)
Demographics 
Age (mean ± SD years) 
Female (%)
 
55 ± 18 
8 (50)
 
54 ± 14 
12 (50)
Comorbidities (%) 
Anemia 
COPD/asthma 
Chronic pain 
Dementia 
Depression 
Diabetes 
DVT/Pe 
Old myocardial infarction 
Heart failure 
Hypertension 
Hyperlipidemia 
Osteoarthritis 
Pneumonia 
Renal insufficiency 
Schizophrenia 
Seizure disorder 
Stroke/transient ischemic attack 
Chronic urinary tract infections
 
3 (19) 
2 (13) 
2 (13) 
2 (13) 
6 (38) 
4 (25) 
6 (38) 
5 (31) 
16 (100) 
6 (38) 
5 (31) 
1 (6) 
2 (13) 
3 (19) 
2 (13) 
2 (13) 
1 (6) 
1 (6)
 
1 (4) 
4 (17) 
2 (8) 
1 (4) 
6 (25) 
4 (17) 
4 (17) 
5 (21) 
5 (21) 
13 (54) 
20 (83) 
2 (8) 
1 (4) 
2 (8) 
2 (8) 
1 (4) 
1 (4) 
0 (0)
Risk factors for QTc prolongation (%) 
Acute coronary syndromes 
Bradycardia 
Congenital long QTc syndrome 
Female gender 
Heart failure 
Hypokalemia 
Hypomagnesemia 
Old myocardial infarction 
QTc .500 msec at baseline† 
receiving .1 QTc-prolonging medication
 
0 (0) 
1 (6) 
0 (0) 
8 (50) 
16 (100) 
6 (38) 
5 (31) 
5 (31) 
3 (19) 
10 (63)
 
24 (100) 
1(4) 
0 (0) 
12 (50) 
5 (21) 
13 (54) 
5 (21) 
5 (21) 
5 (21) 
15 (63)
Number of patients with only 1 risk  
factor for QTc prolongation*
9 (56) 8 (33)
Number with 2 risk factors for QTc  
prolongation*
7 (44) 16 (67)
Notes: *Not including principal diagnosis of either heart failure or acute coronary 
syndromes; †see Table 2 for specific medications. 
Abbreviations:  ACS,  acute  coronary  syndromes;  COPD,  chronic  obstructive 
pulmonary disease; DVT, deep vein thrombosis; Pe, pulmonary embolism; QTc, QT 
interval corrected for heart rate; SD, standard deviation.
of receiving at least one medication that could potentially 
prolong QTc, female gender, and hypokalemia. Not includ-
ing the principal diagnosis as a risk factor, 56% of patients 
with heart failure had only one risk factor for QTc prolonga-
tion, compared with 33% of patients with acute coronary   
syndromes. Table 2 lists the concomitant QTc-prolonging 
medications, their risk for torsades de pointes as per the 
Center for Education and Research at the University of 
Arizona, the length of time the patient had been   receiving Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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Table 2 Description of QTc-prolonging medications
Scheduled medication Patients, n (%) Risk of QTc prolongation* Time receiving medication prior  
to ondansetron exposure
Half-life   
(hours)
Levofloxacin 4 (10) Possible 5 days to 14 days 6–8
Citalopram 8 (20) Possible 1 month to 5 years 35
erythromycin† 4 (10) Accepted 5 days to 10 days 4.6–7.8
Haloperidol 1 (3) Accepted 3 days to 4 days 14
Methadone 4 (10) Accepted 1 year to 3 years 7–60
ranolazine 8 (20) Possible 45 days to 3 years 7–9
risperidone 3 (8) Possible 1 year to 5 years 3–20
Quetiapine 2 (5) Possible 6 months to 4 years 6
Tizanidine 3 (8) Possible 8 days to 3 years 2.5
Ziprasidone 3 (8) Possible 2 months to 3 years 2–7
Venlafaxine 5 (13) Possible 2 months to 4 years 5
Notes: †Used for gastrointestinal motility in patients with diabetes. *QTc risk as determined by the Center for education and research at the University of Arizona. 
Abbreviation: QTc, QT interval corrected for heart rate.
Table 3 Summary of QTc interval changes
QTc outcomes Principal diagnosis Total population 
n = 40 Heart failure 
n = 16
ACS 
n = 24
Baseline, mean ± SD, msec 443 ± 53 444 ± 45 444 ± 47
Baseline, median, msec 435 430 430
Baseline, range, msec 360–570 390–570 360–570
Two hours post-drug, mean ± SD, msec 466 ± 60 463 ± 45 464 ± 50
Two hours post-drug, median, msec 450 450 450
Two hours post-drug, range, msec 410–590 420–580 410–590
Mean change ± SD, msec 20.6 ± 20* 18.3 ± 20** 19.30 ± 18**
Notes: *P , 0.0012; **P , 0.0001. 
Abbreviations: ACS, acute coronary syndromes; SD, standard deviation; QTc, QT interval corrected for heart rate.
the medication prior to ondansetron exposure, and the 
half-life of the drug. All QTc-prolonging medications had 
been initiated prior to hospital admission (range 3 days   
to 5 years), were scheduled medications and not given as 
needed, and were at steady-state as per their half-half. As 
seen in Table 3, the mean and median baseline QTc for 
patients with heart failure were 443 ± 53 msec and 435 msec, 
respectively, and 444 ± 45 msec and 430 msec, respectively, 
for patients with acute coronary syndromes. One hundred 
and twenty minutes after ondansetron administration, the 
mean and median baseline QTc for patients with heart failure 
increased to 466 ± 60 msec and 450 msec, respectively, and 
to 463 ± 45 msec and 450 msec, respectively, for patients 
with acute coronary syndromes. The mean difference in time 
interval between obtaining the baseline electrocardiogram 
and the second electrocardiogram following ondanse-
tron administration was 3.5 ± 2.14 (range 0.5–8) hours. 
  Compared with baseline, the mean change in QTc increased 
significantly by 20.6 ± 20 msec (P , 0.0012), 18.3 ± 20 msec 
(P , 0.0001), and 19.30 ± 18 msec (P , 0.0001) 120 min-
utes after ondansetron administration in patients with heart 
failure, acute coronary syndromes, and the total population, 
respectively. According to gender-related thresholds, five 
patients (31%) in the heart failure group and 11 patients 
(46%) in the acute coronary syndromes group met the criteria   
for prolonged QTc following ondansetron administration. 
No patients experienced torsades de pointes during their 
hospital admission.
Discussion
Our data are consistent with those of two previously pub-
lished studies evaluating the QTc prolongation effect of 
ondansetron.12,13 In a prospective single-blind study, Charbit 
et al evaluated 85 patients with postoperative nausea and vom-
iting who were allocated to receive either 0.75 mg droperidol 
or 4 mg ondansetron intravenously.12   Electrocardiographic 
recordings were obtained before administration and then 
again at minutes 1, 2, 3, 5, 10, and 15 afterwards. According 
to gender-related thresholds, the incidence of QTc prolonga-
tion was 20% and 23% in the ondansetron and droperidol 
groups, respectively. The investigators found a significant 
increase in mean QTc interval during the 15 minutes after Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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antiemetic drug administration in both groups. The maximal 
mean QTc interval lengthening was observed at 3 minutes 
after ondansetron administration, with a mean maximal 
lengthening of 20 ± 13 msec (P , 0.0001) using Bazett’s 
QT correction formula. When using the Fridericia correction 
formula, the QTc interval changes were similar to those found 
by Bazett’s correction formula. In a subset of eight patients, 
electrocardiograms were repeated up to 3 hours following 
drug exposure. In both groups, there was a statistically 
significant reduction in QTc interval when compared with 
baseline QTc (P , 0.05).
In their second study, Charbit et al randomized 16 healthy 
volunteers to receive either placebo, 1 mg of intravenous 
droperidol, 4 mg of intravenous ondansetron, or 1 mg of intra-
venous droperidol plus 4 mg of intravenous ondansetron in 
a double-blind crossover design.13 At intervals of one minute 
for the first 15 minutes and then at minutes 20, 30, 45, 60, 
90, 120, 240, and 600 after the beginning of drug administra-
tion, 10-second digital electrocardiograms were recorded. 
Compared with placebo, the mean maximal difference in 
change in QTc values using the Fridericia correction formula 
were 25 ± 8 msec and 17 ± 10 msec, and 42 ± 21 msec and 
24 ± 12 msec using Bazett’s QT correction formula after dro-
peridol and ondansetron administration, respectively. When 
evaluating time, volunteers receiving intravenous ondansetron 
had QT interval prolongation until minute 4, and then again 
at minutes 7, 8, and 11. In both studies, the investigators con-
cluded that, under controlled conditions, ondansetron induced 
significantly marked prolongation of the QTc interval.12,13
In our study, using Bazett’s formula for QT correction, we 
found that patients with heart failure or acute coronary syn-
dromes with additional risk factors for QT prolongation had 
significant prolonging of their QTc interval by 20.6 ± 20 msec 
(P , 0.0012) and 18.3 ± 20 msec (P , 0.0001), respectively, 
which was similar to the mean maximal changes in QTc 
seen in the other two studies.12,13 However, in our study, this 
prolongation was only seen at 120 minutes after administra-
tion of ondansetron because we did not measure QTc before 
or beyond this time period. We hypothesize that this may 
be due to the fact that all our patients had underlying heart 
disease, which is considered to be one of most important 
nonmodifiable risk factors for QTc prolongation.1,2 Cardiac 
dilatation from long-standing heart failure can result in 
abnormal automaticity. Anaerobic metabolism in ischemic 
myocardial tissue following myocardial infarction can raise 
the resting membrane potential and ultimately lead to an 
abnormal impulse condition.1,2 Additionally, the half-life of 
ondansetron in healthy volunteers is 5.7 hours, so adequate 
drug was still available within the central compartment to 
have a potential impact on myocardial tissue.17
Our study has several of the limitations associated with 
observational data. First, selection bias could exist.   However, 
patients were identified consecutively and enrolled into the 
study according to inclusion criteria in the order that they 
were admitted. Secondly, a mean period of 3.5 ± 2.14 hours 
existed between obtaining a baseline electrocardiogram 
to the second electrocardiogram following intravenous 
ondansetron administration, during which patient’s symp-
toms could deteriorate or improve, thereby impacting the 
QTc interval during that window of time. Third, based on 
animal models, rapid infusion of QTc-prolonging medica-
tions may be more likely to cause arrhythmias than slower 
infusions.3 However, at our institution, it is hospital policy 
that ondansetron be administered via slow intravenous push 
(eg, over five or more minutes). Fourth, we were not able to 
obtain multiple consecutive electrocardiographic measures 
because this was considered a patient safety/quality control 
initiative and could impede nursing work flow in the coro-
nary intensive care unit and step down settings. This was 
stipulated by our institutional medication use evaluation 
committee. Fifth, we used Bazett’s formula for correcting 
the QTc for varying heart rate. While this is the most com-
monly used method in clinical practice, it has been shown 
to overcorrect at short RR intervals and to undercorrect at 
long RR intervals.1 Finally, our data are reflective only of 
the intravenous formulation of ondansetron, and cannot be 
generalized to oral dosing.3
Conclusion
Despite these limitations, the results of our study add to the 
literature showing that intravenous ondansetron in doses 
approved by the Food and Drug Administration can signifi-
cantly prolong the QTc interval. As per the Center for Educa-
tion and Research at the University of Arizona, ondansetron is 
a member of the risk category of “possible drugs” that could 
prolong the QTc interval, leading to torsades de pointes.15 In 
patients admitted for either heart failure or acute coronary 
syndromes with at least one additional risk factor for torsades 
de pointes, we found that this effect could be seen at least 
120 minutes following drug exposure. When considering 
using ondansetron for long-term administration in the inpa-
tient setting, patients with cardiovascular disease who are at 
high risk for drug-induced torsades de pointes should at least 
be monitored via telemetry. From a patient safety perspective, 
ondansetron should be added to the clinician’s list of drugs 
that can possibly prolong the QTc interval.Drug, Healthcare and Patient Safety
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